Semaglutide study links symptom treatment to heart-function changes
Semaglutide improved several measures of cardiac structure and function in people with obesity-related heart failure with preserved ejection fraction, according to a prespecified cardiac magnetic resonance substudy of the randomized CAMEO-SEMA trial.
The findings offer a possible physiological explanation for previously reported benefits of GLP-1 receptor agonists in this group. The investigators said semaglutide has been shown to improve symptoms and to reduce exertional pulmonary artery wedge pressure, a measure used to assess pressure on the left side of the heart during exercise. Until now, however, the cardiac changes that might accompany those haemodynamic improvements had been less clear.
The new analysis was published online in Nature Medicine and was presented at the 2026 American Heart Association Scientific Sessions. It is an early citable version of the peer-reviewed accepted research and remains subject to further editorial revision before the final version of record.
What the substudy measured
The substudy enrolled 49 participants from CAMEO-SEMA. Thirty-three received semaglutide and 16 received placebo; 28 participants were women. Each underwent cardiovascular magnetic resonance imaging at the start of the study and again after 52 weeks. Those scans took place within one day of invasive exercise haemodynamic assessment.
Researchers set left-atrial reservoir strain as the primary imaging endpoint. This measurement describes how the left atrium expands as it receives blood and is one way to evaluate its function. They also prespecified a measurement of left-ventricular filling dynamics: early filling rate indexed to end-diastolic volume, abbreviated eFR/EDV.
HFpEF is a form of heart failure in which the heart’s pumping fraction is preserved, but the heart can have impaired filling and elevated pressures. The source study focused specifically on patients with HFpEF associated with obesity, rather than treating its findings as applying to every cause of the condition.
Changes after 52 weeks
Compared with placebo, semaglutide improved left-atrial reservoir strain by 5.7%, with a reported 95% confidence interval from 0.3% to 9.7%. The result met the study’s stated threshold for statistical significance, with a P value of 0.037.
The difference in eFR/EDV was also in favour of semaglutide: an increase of 0.64 per second, with a 95% confidence interval from 0.42 to 1.00 per second and a P value below 0.0001. The authors interpret this as an improvement in left-ventricular diastolic filling dynamics.
The imaging analysis also reported reductions in left-ventricular mass, restoration of more physiologic left-ventricular geometry, improved right-ventricular function and improved biventricular myocardial mechanics among the other prespecified endpoints. The abstract does not provide effect sizes for each of those secondary measures.
Association with exercise pressures
The study found that improvements in both principal imaging measures were associated with reductions in exercise pulmonary artery wedge pressure. The correlation between change in left-atrial reservoir strain and change in exercise wedge pressure was reported as r = -0.46, with P below 0.001. For eFR/EDV, the correlation was r = -0.65, with P below 0.0001.
Those associations are consistent with the researchers’ conclusion that improved atrial function and ventricular filling could contribute to the haemodynamic effects seen with semaglutide. They do not, on their own, establish that the imaging changes caused the pressure reductions. The substudy was designed to assess these prespecified measurements in a relatively small group, and its reported result is an association between changes.
Why the result matters
GLP-1 medicines have drawn attention for their metabolic and weight-related effects, while heart failure with preserved ejection fraction has remained difficult to treat because it encompasses different underlying disease processes. The CAMEO-SEMA imaging results point toward a mechanism that involves the heart itself: better left-atrial function, better filling dynamics and broader changes in cardiac structure and mechanics.
For clinicians and researchers, the work adds imaging evidence to the existing clinical and haemodynamic picture in obesity-related HFpEF. For patients, it does not change the need for individual medical assessment or show that the results can be generalized to people without obesity-related HFpEF.
The trial is registered at ClinicalTrials.gov as NCT05371496. Further analysis and the final published version will be important for clarifying the durability and clinical meaning of the reported structural and functional changes.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
